Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Stock Information for Vaxil Bio Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaxil Bio Ltd.

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
Aptose Announces Auditor Not Standing for Re-Appointment
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
Aptose Reports Year End 2024 Results and Corporate Highlights
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Aptose Announces Reverse Share Split
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.